Because IRI may improve symptoms of macular edema in BRVO by decreasing RFV and vessel diameters, data on changes in these variables after anti-VEGF treatment may reveal a new treatment target for BRVO or a method for evaluating its severity. The gene discussed is VEGFA; the disease is macular retinal edema.